Table 2

Characteristics of patients with PMR after ICI treatment for cancer

PatientsSex/age, yearsType of cancerICIDate of first ICI exposureDate of IrAEType of rheumatic IrAEIrAE response to treatmentAutoantibody resultsTumour response
7F 76MesotheliomaAnti-PDL1June 2014March 2015PMRResolution with prednisone 20 mg/day then taperedANA, RF, CCP negativeProgression switch for pemetrexed
8M 69Gastric adenocarcinomaPembrolizumabSeptember 2016October 2016PMRResolution with prednisone 20 mg/day then taperedANA, RF, CCP negativeProgression
9M 62Colon adenocarcinomaNivolumab+ipilimumab (four cycles) then nivolumab aloneJune 2015October 2015PMRResolution with prednisone 60 mg/day then taperedANA 1:320 with anti-ENA negative, RF, CCP negativeStable disease
10M 68Metastatic melanomaNivolumabAugust 2016August 2016PMRResolution with prednisone 40 mg/day then taperedRF, CCP negativeStable disease
  • ANA, antinuclear antibodies; anti-ENA, anti-extractable antibodies; CCP, cyclic citrullinated peptide; F, female; ICI, immune checkpoint inhibitor; IrAE, immune-related adverse event; M, male; PDL1, programmed cell death ligand protein 1; PMR, polymyalgia rheumatica; RF, rheumatoid factor.